Embecta Corp. (NASDAQ:EMBC – Get Free Report)’s stock price passed below its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of $6.13 and traded as low as $5.98. Embecta shares last traded at $6.09, with a volume of 715,677 shares trading hands.
Analysts Set New Price Targets
Separately, Weiss Ratings raised Embecta from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, November 2nd. Four research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Reduce” and a consensus target price of $11.00.
View Our Latest Analysis on EMBC
Embecta Stock Down 1.0%
Insider Transactions at Embecta
In other news, Director Milton Mayo Morris sold 6,293 shares of the business’s stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $5.88, for a total transaction of $37,002.84. Following the completion of the transaction, the director owned 53,828 shares of the company’s stock, valued at approximately $316,508.64. The trade was a 10.47% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.30% of the stock is owned by insiders.
Institutional Trading of Embecta
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Pathstone Holdings LLC boosted its stake in shares of Embecta by 2.6% during the 3rd quarter. Pathstone Holdings LLC now owns 71,246 shares of the company’s stock worth $419,000 after purchasing an additional 1,819 shares during the period. Fifth Third Bancorp boosted its stake in shares of Embecta by 44.2% in the third quarter. Fifth Third Bancorp now owns 7,061 shares of the company’s stock worth $40,000 after buying an additional 2,163 shares during the last quarter. Allworth Financial LP lifted its position in shares of Embecta by 234.1% during the 3rd quarter. Allworth Financial LP now owns 4,707 shares of the company’s stock valued at $27,000 after buying an additional 3,298 shares in the last quarter. GAMMA Investing LLC boosted its stake in Embecta by 101.5% during the 3rd quarter. GAMMA Investing LLC now owns 10,898 shares of the company’s stock worth $62,000 after purchasing an additional 5,490 shares during the last quarter. Finally, State of Wyoming raised its holdings in shares of Embecta by 61.5% during the 1st quarter. State of Wyoming now owns 24,587 shares of the company’s stock worth $217,000 after acquiring an additional 9,366 shares during the period. 93.83% of the stock is owned by hedge funds and other institutional investors.
About Embecta
Embecta is a medical device company focused on products for people who use insulin to manage diabetes. Its portfolio includes pen needles, insulin syringes and safety injection devices, serving both individuals and healthcare professionals. The company was formed in 2022 when Becton, Dickinson and Company (BD) separated its diabetes care business into an independent company. Embecta continues to build on that business’s history of developing injection devices for diabetes care. Embecta serves customers in markets around the world.
Featured Articles
- Five stocks we like better than Embecta
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for Embecta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Embecta and related companies with MarketBeat.com's FREE daily email newsletter.
